Weleader Biomedical Co (ROCO:7713) EBIT: NT$269 Mil (TTM As of Dec. 2025)


ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
47 GF Score
Price NT$70.10
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co EBIT?

Weleader Biomedical Co ROCO:7713 -1.54% 47 EBIT is NT$269 Mil as of Dec. 2025. GuruFocus rates ROCO:7713 with a GF Score™ of 47/100. The stock has 5 warning signs investors should review.

Weleader Biomedical Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$76 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$269 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Weleader Biomedical Co's annualized ROC % for the quarter that ended in Dec. 2025 was 13.34%. Weleader Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 18.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Weleader Biomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.24%.


Weleader Biomedical Co  (ROCO:7713) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Weleader Biomedical Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=296.424 * ( 1 - 20.39% )/( (1735.588 + 1801.379)/ 2 )
=235.9831464/1768.4835
=13.34 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2323.12 - 305.111 - ( 298.641 - max(0, 478.006 - 760.427+298.641))
=1735.588

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2448.985 - 312.893 - ( 334.713 - max(0, 432.302 - 780.386+334.713))
=1801.379

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Weleader Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=303.756/( ( (1498.548 + max(124.333, 0)) + (1588.84 + max(102.025, 0)) )/ 2 )
=303.756/( ( 1622.881 + 1690.865 )/ 2 )
=303.756/1656.873
=18.33 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(307.225 + 126.658 + 5.356) - (305.111 + 0 + 9.795)
=124.333

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(304.092 + 117.933 + 5.227) - (312.893 + 0 + 12.334)
=102.025

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Weleader Biomedical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=269.001/3716.992
=7.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Weleader Biomedical Co EBIT Related Terms


Weleader Biomedical Co EBIT Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co EBIT Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 137.62 196.75 199.24 221.00 269.00

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.72 52.70 64.05 76.32 75.94

ROCO:7713 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Weleader Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Weleader Biomedical Co EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Weleader Biomedical Co's EV-to-EBIT falls into.


ROCO:7713
47GF Score
Weleader Biomedical Co Ltd ROCO:7713
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Weleader Biomedical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$269 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$269 Mil mean?
Weleader Biomedical Co (ROCO:7713) has a EBIT of NT$269 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Weleader Biomedical Co.
Is Weleader Biomedical Co's EBIT too high?
Weleader Biomedical Co's current EBIT is NT$269 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's EBIT compare to ABT and SYK?
Weleader Biomedical Co's EBIT of NT$269 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Weleader Biomedical Co. Weleader Biomedical Co's current EBIT is NT$269 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current EBIT of NT$269 Mil. The current EBIT is NT$269 Mil. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current EBIT is NT$269 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score

Get the complete analysis for ROCO:7713

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.10
Price